In light of all the dour economic news you might be surprised to learn that a small overall loss in the value of biotech investments nevertheless left the industry as the leader in performance among 12 different categories ranked by the S&P. Pictet Funds' Luxembourg-domiciled $1.8 billion Biotech fund gained 3.5 per cent, the only fund out 67 S&P Fund Services-rated global sector funds that had a positive return in the third quarter. Report